Stock Analiz

Passage BIO, Inc. PASG

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026

$4.25Market cap $14M
Open the interactive analysis →

Passage BIO, Inc. (PASG) is a healthcare company listed in the US with a market value of about $14M.

Its overall Stock Analiz score is 0.0 out of 5 (weak). The strongest part is value (0/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -62%.

About Passage BIO

Passage BIO is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 14% over three years (dilution for shareholders).

Score: 0.0 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • —

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B273.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-62.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal year2025202420232022202120202019
Revenue———————
Net income-$46M-$65M-$102M-$136M-$185M-$112M-$46M
Free cash flow—-$48M—————
EPS (diluted)$-14.35$-21.04$-36.49$-49.05$-68.28$-57.10$-211.31
Net margin———————
ROIC-91.1%-64.1%-62.2%-47.9%-46.1%-29.3%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Passage BIO pay a dividend?

Not currently.

Is Passage BIO a good stock to buy?

We do not give buy or sell advice. Passage BIO scores 0.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.